Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Cancer Chemother Pharmacol ; 78(5): 881-893, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27590709

RESUMO

PURPOSE: Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs. These side effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy, resulting in dose reductions and treatment discontinuation. Here, we aimed to review the experimental evidence regarding possible new targets for the management of irinotecan- and 5-FU-related intestinal mucositis. METHODS: A literature search was performed using the PubMed and MEDLINE databases. No publication time limit was set for article inclusion. RESULTS: Here, we found that clinical management of intestinal mucositis and diarrhea is somewhat ineffective at reducing symptoms, possibly due to a lack of specific targets for modulation. We observed that IL-1ß contributes to the apoptosis of enterocytes in mucositis induced by 5-FU. However, 5-FU-related mucositis is far less thoroughly investigated with regard to specific molecular targets when compared to irinotecan-related disease. Several studies have proposed that a correlation exists between the intestinal microbiota, the enterohepatic recirculation of active metabolites of irinotecan, and the establishment of mucositis. However, as reviewed here, this association seems to be controversial. In addition, the pathogenesis of irinotecan-induced mucositis appears to be orchestrated by interleukin-1/Toll-like receptor family members, leading to epithelial cell apoptosis. CONCLUSIONS: IL-1ß, IL-18, and IL-33 and the receptors IL-1R, IL-18R, ST2, and TLR-2 are potential therapeutic targets that can be modulated to minimize anticancer agent-associated toxicity, optimize cancer treatment dosing, and improve clinical outcomes. In this context, the pathogenesis of mucositis caused by other anticancer agents should be further investigated.


Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Antineoplásicos Fitogênicos/efeitos adversos , Camptotecina/análogos & derivados , Fluoruracila/efeitos adversos , Enteropatias/induzido quimicamente , Mucosite/induzido quimicamente , Camptotecina/efeitos adversos , Citocinas/metabolismo , Humanos , Enteropatias/metabolismo , Enteropatias/patologia , Irinotecano , Mucosite/metabolismo , Mucosite/patologia , Receptores de Citocinas/efeitos dos fármacos , Receptores de Citocinas/metabolismo
2.
Cytokine ; 61(1): 46-9, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23107827

RESUMO

BACKGROUND: 5-Fluorouracil (5-FU) induces intestinal mucositis, which is characterized by epithelial ulcerations in the mucosa and clinical manifestations, such as pain and dyspeptic symptoms. Cytokines participate in the inflammatory and functional events of intestinal mucositis. IL-4 is an important mediator of intestinal inflammation, with either anti-inflammatory or pro-inflammatory functions, depending on the model of intestinal inflammation. This study aimed to evaluate the role of IL-4 in 5-FU-induced intestinal mucositis. METHODS: IL-4+/+ or IL-4-/- mice (25-30 g) were intraperitoneally injected with 5-FU (450 mg/Kg) or saline (C). After 3 days, the mice were sacrificed and the duodenum was evaluated for epithelial damage, MPO activity and cytokine concentration. RESULTS: 5-FU induced significant damage in the intestinal epithelium of IL-4+/+ mice (reduction in the villus/crypt ratio: control=3.31±0.21 µm, 5-FU=0.99±0.10 µm). However, the same treatment did not induce significant damage in IL-4-/- mice (5-FU=2.87±0.19 µm) compared to wild-type mice. 5-FU-induced epithelial damage increased the MPO activity (neutrophil number) and the level of pro-inflammatory cytokines (IL-4, TNF-α, IL-1ß and CXCL-8) in the duodenum. These results were not observed in IL-4-/- mice treated with 5-FU. CONCLUSION: Our data suggest that IL-4 participates as a pro-inflammatory cytokine in a 5-FU-induced intestinal damage model and suggests that IL-4 antagonists may be novel therapeutics for this condition.


Assuntos
Duodeno/imunologia , Fluoruracila/farmacologia , Interleucina-4/genética , Interleucina-4/metabolismo , Mucosa Intestinal/efeitos dos fármacos , Animais , Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/farmacologia , Duodeno/lesões , Fluoruracila/efeitos adversos , Interleucina-1beta/metabolismo , Interleucina-8/metabolismo , Mucosa Intestinal/patologia , Intestinos/imunologia , Intestinos/lesões , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Mucosite/patologia , Fator de Necrose Tumoral alfa/metabolismo
3.
Arq Gastroenterol ; 48(1): 80-5, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21537548

RESUMO

CONTEXT: Methotrexate and other anticancer agents can induce intestinal mucositis, which is one of the most common limiting factor that prevent further dose escalation of the methotrexate. OBJECTIVES: To evaluate the gastric emptying and gastrointestinal transit of liquids in methotrexate-induced intestinal mucositis. METHODS: Wistar rats received methotrexate (2.5 mg/kg/day for 3 days, subcutaneously) or saline. After 1, 3 and 7 days, sections of duodenum, jejunum and ileum were removed for assessment of epithelial damage and myeloperoxidase activity (biochemical marker of granulocyte infiltration). Others rats were pre-treated with methotrexate or saline, gavage-fed after 3 or 7 days with a standard test liquid meal, and sacrificed 10, 20 or 30-min later. Gastric and small intestine dye recoveries were measured by spectrophotometry. RESULTS: After 3 days of methotrexate, there was an epithelial intestinal damage in all segments, with myeloperoxidase activity increase in both in duodenum and ileum. Seven days after methotrexate, we observed a complete reversion of this intestinal damage. There was an increase in gastric dye recoveries after 10, 20, and 30-min post-prandial intervals after 3 days, but not after 7 days, of methotrexate. Intestine dye recoveries were decreased in the first and second segments at 10 min, in the third at 20 min, and in the second and third at 30 min, only after 3 days of methotrexate treatment. CONCLUSION: Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats.


Assuntos
Antimetabólitos Antineoplásicos/toxicidade , Esvaziamento Gástrico/efeitos dos fármacos , Trânsito Gastrointestinal/efeitos dos fármacos , Metotrexato/toxicidade , Mucosite/induzido quimicamente , Animais , Masculino , Mucosite/complicações , Peroxidase/metabolismo , Ratos , Ratos Wistar , Espectrofotometria , Fatores de Tempo
4.
Arq. gastroenterol ; 48(1): 80-85, Jan.-Mar. 2011. graf
Artigo em Inglês | LILACS | ID: lil-583765

RESUMO

CONTEXT: Methotrexate and other anticancer agents can induce intestinal mucositis, which is one of the most common limiting factor that prevent further dose escalation of the methotrexate. OBJECTIVES: To evaluate the gastric emptying and gastrointestinal transit of liquids in methotrexate-induced intestinal mucositis. METHODS: Wistar rats received methotrexate (2.5 mg/kg/day for 3 days, subcutaneously) or saline. After 1, 3 and 7 days, sections of duodenum, jejunum and ileum were removed for assessment of epithelial damage and myeloperoxidase activity (biochemical marker of granulocyte infiltration). Others rats were pre-treated with methotrexate or saline, gavage-fed after 3 or 7 days with a standard test liquid meal, and sacrificed 10, 20 or 30-min later. Gastric and small intestine dye recoveries were measured by spectrophotometry. RESULTS: After 3 days of methotrexate, there was an epithelial intestinal damage in all segments, with myeloperoxidase activity increase in both in duodenum and ileum. Seven days after methotrexate, we observed a complete reversion of this intestinal damage. There was an increase in gastric dye recoveries after 10, 20, and 30-min post-prandial intervals after 3 days, but not after 7 days, of methotrexate. Intestine dye recoveries were decreased in the first and second segments at 10 min, in the third at 20 min, and in the second and third at 30 min, only after 3 days of methotrexate treatment. CONCLUSION: Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats.


CONTEXTO: Metotrexato e outros agentes anticâncer podem induzir uma mucosite intestinal, que é um dos fatores de limitante mais comum que limitam o aumento escalonado da dose do metotrexato. OBJETIVOS: Avaliar o esvaziamento gástrico e o trânsito gastrointestinal de líquidos na mucosite intestinal induzida por metotrexato. MÉTODOS: Ratos Wistar, receberam metotrexato (2.5 mg/kg/dia por 3 dias, subcutâneo) ou salina. Após 1, 3 ou 7 dias, secções do duodeno, jejuno e íleo foram retirados para análise morfométrica e dosagem da atividade de mieloperoxidase (marcador bioquímico da infiltração de neutrófilos). Outros ratos foram pré-tratados com metotrexato ou salina, após 3 ou 7 dias, foram alimentados mediante gavagem com uma refeição teste e sacrificados após 10, 20 e 30 minutos. As retenções fracionais do corante no estômago e em três segmentos do intestino delgado foram determinados por espectrofotometria. RESULTADOS: Após 3 dias do metotrexato, houve lesão do epitélio intestinal em todos os segmentos, com aumento da atividade de mieloperoxidase, no duodeno e íleo. Sete dias após o metotrexato, foi observada completa reversão da lesão intestinal. Observou-se ainda retardo no esvaziamento gástrico após 10 min, 20 min e 30 min, após 3 dias, mas não após 7 dias do tratamento com metotrexato. A retenção fracional dos segmentos do intestino foi reduzida no primeiro e segundo segmentos após 10 min, e no terceiro segmento após 30 min da administração da refeição, somente 3 dias após o tratamento com metotrexato. CONCLUSÃO: A mucosite intestinal induzida por metotrexato retarda o esvaziamento gástrico e o trânsito gastrointestinal de líquidos em ratos acordados.


Assuntos
Animais , Masculino , Ratos , Antimetabólitos Antineoplásicos/toxicidade , Esvaziamento Gástrico/efeitos dos fármacos , Trânsito Gastrointestinal/efeitos dos fármacos , Metotrexato/toxicidade , Mucosite/induzido quimicamente , Mucosite/complicações , Peroxidase/metabolismo , Ratos Wistar , Espectrofotometria , Fatores de Tempo
5.
Cancer Chemother Pharmacol ; 68(3): 713-20, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21153821

RESUMO

PURPOSE: Gastrointestinal mucositis is a common side effect of cancer chemotherapy. Platelet-activating factor (PAF) is produced during gut inflammation. There is no evidence that PAF participates in antineoplastic-induced intestinal mucositis. This study evaluated the role of PAF in 5-fluorouracil (5-FU)-induced intestinal mucositis using a pharmacological approach and PAF receptor knockout mice (PAFR(-/-)). METHODS: Wild-type mice or PAFR(-/-) mice were treated with 5-FU (450 mg/kg, i.p.). Other mice were treated with saline or BN52021 (20 mg/kg, s.c.), an antagonist of the PAF receptor, once daily followed by 5-FU administration. After the third day of treatment, animals were sacrificed and tissue samples from the duodenum were removed for morphologic evaluation. In addition, myeloperoxidase activity and the cytokine concentration were measured. RESULTS: 5-FU treatment decreased the duodenal villus height/crypt depth ratio, increased MPO activity, and increased the concentration of TNF-α, IL-1ß and KC in comparison with saline-treated animals. In PAFR(-/-) mice and PAFR antagonist-treated mice, 5-FU-dependent intestinal damage was reduced and a decrease in duodenal villus height/crypt depth ratio was attenuated. However, the 5-FU-dependent increase in duodenum MPO activity was not affected. Without PAFR activation, 5-FU treatment did not increase the TNF-α, IL-1ß and KC concentration. CONCLUSIONS: In conclusion, our study establishes the role of PAFR activation in 5-FU-induced intestinal mucositis. This study implicates treatment with PAFR antagonists as novel therapeutic strategy for this condition.


Assuntos
Antimetabólitos Antineoplásicos/toxicidade , Fluoruracila/toxicidade , Enteropatias/induzido quimicamente , Enteropatias/patologia , Mucosite/induzido quimicamente , Mucosite/patologia , Fator de Ativação de Plaquetas/fisiologia , Animais , Citocinas/metabolismo , Duodeno/metabolismo , Ginkgolídeos/farmacologia , Mucosa Intestinal/patologia , Lactonas/farmacologia , Contagem de Leucócitos , Leucopenia/sangue , Leucopenia/induzido quimicamente , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Peroxidase/metabolismo , Fator de Ativação de Plaquetas/antagonistas & inibidores , Fator de Ativação de Plaquetas/genética , Receptores do Fator de Crescimento Derivado de Plaquetas/genética
6.
Cancer Chemother Pharmacol ; 63(1): 91-8, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18324404

RESUMO

AIM: To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis. MATERIALS AND METHODS: Wistar rats received 5-FU (150 mg kg(-1), i.p.) or saline. After the 1st, 3rd, 5th, 15th and 30th day, sections of duodenum, jejunum and ileum were removed for assessment of epithelial damage, apoptotic and mitotic indexes, MPO activity and GSH concentration. In order to study gastrointestinal motility, on the 3rd or 15th day after 5-FU treatment, gastric emptying in vivo was measured by scintilographic method, and stomach or duodenal smooth muscle contractions induced by CCh were evaluated in vitro. RESULTS: On the third day of treatment, 5-FU induced a significant villi shortening, an increase in crypt depth and intestinal MPO activity and a decrease in villus/crypt ratio and GSH concentration. On the first day after 5-FU there was an increase in the apoptosis index and a decrease in the mitosis index in all intestinal segments. After the 15th day of 5-FU treatment, a complete reversion of all these parameters was observed. There was a delay in gastric emptying in vivo and a significant increase in gastric fundus and duodenum smooth muscle contraction, after both the 3rd and 15th day. CONCLUSION: 5-FU-induced gastrointestinal dysmotility outlasts intestinal mucositis.


Assuntos
Antimetabólitos Antineoplásicos/toxicidade , Fluoruracila/toxicidade , Motilidade Gastrointestinal/efeitos dos fármacos , Enteropatias/fisiopatologia , Mucosite/fisiopatologia , Animais , Apoptose/efeitos dos fármacos , Carbacol/farmacologia , Esvaziamento Gástrico/efeitos dos fármacos , Fundo Gástrico/patologia , Glutationa/análise , Enteropatias/induzido quimicamente , Intestino Delgado/patologia , Masculino , Índice Mitótico , Mucosite/induzido quimicamente , Peroxidase/análise , Distribuição Aleatória , Ratos , Ratos Wistar , Fatores de Tempo
7.
Exp Toxicol Pathol ; 59(6): 425-30, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18234483

RESUMO

AIM: Acrolein (ACR) is a urinary metabolite of cyclophosphamide (CPS) and ifosfamide (IFS), which has been demonstrated to be the causative agent of hemorrhagic cystitis (HC), induced by these compounds. In this study, we investigate the participation of cyclooxygenase-2 (COX-2) on ACR-induced HC. METHODS: Male Wistar rats (150-200g; six rats per group) were treated with distilled water or intravesical ACR and analyzed by changes in bladder wet weight, macroscopic and microscopic parameters and COX-2 expression. RESULTS: COX-2 immunohistochemical expression was significant 12h after ACR administration mainly in subepithelial cells. ACR injection also alters some macroscopic and microscopic parameters in bladder of rats analyzed by Gray's criteria. CONCLUSIONS: COX-2 participates in the pathogenesis of ACR-induced HC first seen 12h after initial contact between ACR and urothelium.


Assuntos
Acroleína/toxicidade , Ciclo-Oxigenase 2/biossíntese , Cistite/induzido quimicamente , Hemorragia/induzido quimicamente , Acroleína/metabolismo , Administração Intravesical , Animais , Cistite/complicações , Cistite/enzimologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Indução Enzimática , Hemorragia/complicações , Hemorragia/enzimologia , Masculino , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Wistar , Fatores de Tempo , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/enzimologia , Bexiga Urinária/patologia
8.
Dig Dis Sci ; 52(1): 119-25, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17160473

RESUMO

This study was designed to evaluate the protective effect of amifostine on indomethacin-induced gastric damage, and the role of increased gastric non-protein sulfhydryl groups (NP-SH) and decreased leukocyte adherence in this event. Wistar rats were pretreated with amifostine (10, 30, or 90 mg/kg intraperitoneal (i.p.) or subcutaneous (s.c.)) or saline. After 30 min, the rats received indomethacin (20 mg/kg, by gavage) and were then killed 3 hr later. Macroscopic and microscopic gastric damage, concentration of gastric NP-SH, prostaglandin E2 (PGE2), and mesenteric leukocyte adherence (intravital microscopy) were assessed. Amifostine prevented significantly (P < 0.05), macroscopic or microscopic, indomethacin-induced gastric damage, and increased gastric NP-SH, in a dose-dependent manner, with a maximal effect at a dose of 90 mg/kg. Subcutaneous, but not i.p., amifostine administration decreased (P < 0.05) the indomethacin-induced increase in leukocyte adherence. Indomethacin-induced PGE2 depletion was not reversed by amifostine. Amifostine has a protective effect against indomethacin-induced gastropathy by increasing gastric NP-SH and decreasing leukocyte adherence.


Assuntos
Amifostina/uso terapêutico , Anti-Inflamatórios não Esteroides/efeitos adversos , Mucosa Gástrica/efeitos dos fármacos , Indometacina/efeitos adversos , Protetores contra Radiação/uso terapêutico , Gastropatias/prevenção & controle , Adesividade , Animais , Dinoprostona/metabolismo , Inibidores Enzimáticos/farmacologia , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patologia , Glibureto/farmacologia , Imuno-Histoquímica , Leucócitos/fisiologia , Masculino , NG-Nitroarginina Metil Éster/farmacologia , Ratos , Ratos Wistar , Gastropatias/etiologia , Compostos de Sulfidrila/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...